Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Sarcoma 6Recurrence 3Osteosarcoma 3Rhabdomyosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Breast Neoplasms 2Vomiting 1Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Rhabdoid Tumor 1Neurofibrosarcoma 1Neoplasm Metastasis 1Nausea 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Liposarcoma 1Leukemia, Biphenotypic, Acute 1Leiomyosarcoma 1Hypersensitivity 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Heart Failure 1Fibrosarcoma 1

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × Dexrazoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡